Tumor Necrosis Factor Receptor Superfamily, Member 17 Proteins (TNFRSF17)

Human Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) interaction partners

1. Expression patterns of BAFF (show TNFSF13B Proteins) and its receptor BCMA differ according to lupus nephritis class.

2. High BCMA expression is associated with primary central nervous system lymphoma.

3. soluble BCMA sequesters circulating BAFF (show TNFSF13B Proteins), thereby preventing it from performing its signaling to stimulate normal B-cell and plasma cell development, resulting in reduced polyclonal antibody levels in multiple myeloma patients.

4. Studied expression of B-cell maturation antigen (BCMA) in osteoblasts and the toxic effect of chromium on its expression; found BCMA is involved in osteogenesis of osteoblasts; chromium downregulates expression of BCMA in osteoblasts.

5. BCMA has other contributors for ligands binding except DxL motif. The affinity of BCMA for APRIL higher than for BAFF (show TNFSF13B Proteins) may be caused by the segment outside of the conservative DxL motif. Moreover, the exposition of new binding modes of BCMA2 interacting with APRIL may establish the foundation of designing novel drugs in the future

6. New molecular mechanisms of in vivo Multiple Myeloma (MM) growth and immunosuppression critically dependent on BCMA and APRIL in the Bone marrow microenvironment, further supporting targeting this prominent pathway in MM.

7. We have identified a specific serum protein, BCMA, as a novel independent marker for both monitoring and predicting outcomes for MM patients. We have shown that sBCMA is elevated in MM patients, and can be used to follow their disease status, PFS and OS.

8. The expression levels of serum BAFF (show TNFSF13B Proteins) and the three receptors (TACI (show TNFRSF13B Proteins), BCMA and BAFF-R (show TNFRSF13C Proteins)) in non-Hodgkin lymphoma patients were significantly higher than in healthy controls.

9. Decreased BCMA expression on peripheral B cells according to severe disease activity suggests that BCMA plays an important regulating role in B-cell hyperactivity and immune tolerance homeostasis in systemic lupus erythematosus patients

10. results suggest that Akt (show AKT1 Proteins) and JNK (show MAPK8 Proteins) pathways are involved in the regulation of B-cell maturation antigen (BCMA)

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) interaction partners

1. high affinity antibody blocks the binding of the native ligands APRIL and BAFF (show TNFSF13B Proteins) to BCMA. This finding is rationalized by the high resolution crystal structure of the Fab (show FANCB Proteins) fragment in complex with the extracellular domain of BCMA

2. Elimination of B lymphocyte stimulator (show TNFSF13B Proteins) receptor 3 (BR-3) and BCMA inhibits the development of SLE in NZM mice.

3. we have identified a novel role for BCMA to control excess BAFF (show TNFSF13B Proteins) production in murine lupus through restraining the accumulation of BAFF (show TNFSF13B Proteins)-producing neutrophils.

4. Heteromers consisting of one BAFF (show TNFSF13B Proteins) and two APRIL bind to receptor TACI (show TNFRSF13B Proteins), BCMA but not to BAFFR (show TNFRSF13C Proteins).

5. BCMA is dispensable for the development of SLE in NZM mice. BAFF (show TNFSF13B Proteins)-BCMA interactions contribute to SLE.

6. Study reveals that BCMA works to control B cell homeostasis and self-tolerance in systemic autoimmunity.

7. Blimp-1 (show PRDM1 Proteins) is a positive regulator of the expression of BCMA gene in mouse plasma cells.

8. The 5'-flanking sequence from -820 to +145 bp of BCMA is of promoter activity.

9. A vital role of BCMA in bone marrow plasma cell survival.

10. B cell maturation antigen, the receptor for a proliferation-inducing ligand (show TNFSF13 Proteins) and B cell-activating factor (show TNFSF13B Proteins) of the TNF (show TNF Proteins) family, induces antigen presentation in B cells.